Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Biochemically Recurrent Prostate Carcinoma: early-phase trial registry
6 of 11 indexed Biochemically Recurrent Prostate Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Biochemically Recurrent Prostate Carcinoma: 11 US clinical trials tracked, 6 recruiting.
Biochemically Recurrent Prostate Carcinoma is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 3 of these trials.
Enrollment posture brief
Registry condition biochemically-recurrent-prostate-carcinoma
OPEN 6 | RECR 55% | LATE 2 | EARLY 9 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
Biochemically Recurrent Prostate Carcinoma lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Biochemically Recurrent Prostate Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Biochemically Recurrent Prostate Carcinoma is recruiting above its size-band peers.
6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Biochemically Recurrent Prostate Carcinoma research.
Mayo Clinic accounts for 3 of 11 trials (27.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Biochemically Recurrent Prostate Carcinoma enrolment sits around 118 participants.
Median target enrolment is 118 among the 11 trials that report a genuine target (sentinel values excluded). 5 of those (45.5%) plan for fewer than 100 participants.
-
Biochemically Recurrent Prostate Carcinoma research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ECOG-ACRIN Cancer Research Group
NCT04423211
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic
NCT06378866
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
M.D. Anderson Cancer Center
NCT05054296
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
NCT06205316
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Mayo Clinic
NCT07073794
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
Northwestern University
NCT06813898
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
NCT04777071
RElugolix VErsus LeUprolide Cardiac Trial
Emory University
NCT05320406
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Emory University
NCT06105918
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT04050215
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
M.D. Anderson Cancer Center
NCT04978675
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Biochemically Recurrent Prostate Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Biochemically Recurrent Prostate Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Biochemically Recurrent Prostate Carcinoma page
11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Biochemically Recurrent Prostate Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Biochemically Recurrent Prostate Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Biochemically Recurrent Prostate Carcinoma condition card totals 11 registered trials; most-linked intervention Computed Tomography; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.